Roland Magnusson/iStock Editorial via Getty Images Nona Biosciences has entered into a license agreement with AstraZeneca ( NASDAQ: AZN ) for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology, it said late on Wednesday. Under the terms of the agreement, Nona Biosciences shall receive $19 million upon completion of the transaction, and is also eligible to receive an additional $10 million in potential near-term milestone payments and up to $575 million upon achieving specified development, regulatory, and commercial milestones. In addition, Nona is eligible to receive payments for the option programs should AstraZeneca ( AZN ) exercise these options.
Source: Press Release More on AstraZeneca AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript AstraZeneca projects $80B in revenue by 2030 AstraZeneca, Amgen release mid-stage data on Tezspire for COPD.